Publications

2018

1. Abacavir use and risk of recurrent myocardial infarction. Sabin CA, Ryom L , d'Arminio Monforte A, Hatleberg CI, Pradier C, El-Sadr W, Kirk O, Weber R ,Phillips AN,  Mocroft A,  Bonnet F,  Law M, de Wit S, Reiss P, Lundgren JD; D:A:D Study Group.
AIDS. 2018;32(1):79-88. Abstract

2. Airflow limitation in people living with HIV and matched uninfected controls. Ronit A, Lundgren J, Afzal S, Benfield T, Roen A, Mocroft A, Gerstoft J, Nordestgaard BG, Vestbo J, Nielsen SD; Copenhagen Co-morbidity in HIV infection (COCOMO) study group.
Thorax. 2018 [Epub ahead of print] Abstract

3. Cytomegalovirus Viral Load in Bronchoalveolar Lavage to Diagnose Lung Transplant Associated CMV Pneumonia. Lodding IP, Schultz HH, Jensen JU, Kirkby N, Perch M, Andersen C, Lundgren JD, Iversen M.
Transplantation. 2018;102(2):326-332. Abstract

4. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, Kristoffersen KB, Burkhardt O, Welte T, Schroeder S, Nobre V, Wei L, Bucher HC, Annane D, Reinhart K, Falsey AR, Branche A, Damas P, Nijsten M, de Lange DW, Deliberato RO, Oliveira CF, Maravić-Stojković V, Verduri A, Beghé B, Cao B, Shehabi Y, Jensen JS, Corti C, van Oers JAH, Beishuizen A, Girbes ARJ, de Jong E, Briel M, Mueller B.
Lancet Infect Dis. 2018 ;18(1):95-107. Abstract

5. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C,Kirk O, Sambatakou H, Fätkenheuer G, Yust I, Schmid P, Gottfredsson M, Khromova I, Jilich D, Flisiak R, Smidt J, Rozentale B, Radoi R, Losso MH, Lundgren JD, Mocroft A; EuroSIDA Study Group.
HIV Med. 2018;19(2):102-117. Abstract

6. Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study. Ronit A, Sharma S, Baker JV, Mngqibisa R, Delory T, Caldeira L, Ndembi N, Lundgren JD, Phillips AN; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) Strategic Timing of Antiretroviral Treatment (START) Study Group
J Infect Dis. 2018;217(3):405-412. Abstract 

7. The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. Shepherd L, Borges ÁH, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M, Viard JP, Bogner JR, Gargalianos-Kakolyris P, Mussini C, Mansinho K, Yust I, Paduta D, Jilich D, Smiatacz T, Radoi R, Tomazic J, Plomgaard P, Frikke-Schmidt R, Lundgren J, Mocroft A; EuroSIDA in EuroCOORD.
HIV Med. 2018;19(2):90-101. Abstract

8.  Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV? Mocroft A1, Laut K2, Reiss P3,4, Gatell J5, Ormaasen V6, Cavassini M7, Hadziosmanovic V8, Mansinho K9, Pradier C10, Vasylyev M11, Mitsura V12, Vandekerckhove L13, Ostergaard L14, Clarke A15, Degen O16, Mulcahy F17, Castagna A18,19, Sthoeger Z20, Flamholc L21, Sedláček D22, Mozer-Lisewska I23, Lundgren JD2; EuroSIDA Study.
AIDS. 2018 ;32(2):205-215. Abstract

9. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. Molina JM, Grund B, Gordin F, Williams I, Schechter M, Losso M, Law M, Ekong E, Mwelase N, Skoutelis A, Wiselka MJ, Vandekerckhove L, Benfield T, Munroe D, Lundgren JD, Neaton JD; INSIGHT START study group
Lancet HIV. 2018  [Epub ahead of print]. Abstract

 

2017

1. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial. J O'Connor, MJ Vjecha, AN Phillips, B Angus, D Cooper, B Grinsztejn, G Lopardo, S Das, R Wood, A Wilkin, H Klinker, P Kantipong, KL Klingman, D Jilich, E Herieka, E Denning, I Abubakar, F Gordin, JD Lundgren; INSIGHT START study group.
Lancet HIV. 2017, 4(3) e105-e112. Abstract

2 Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials.
P Ljungman, M Boeckh, HH Hirsch, F Josephson, J Lundgren, G Nichols, A Pikis, RR Razonable, V Miller, PD Griffiths; Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum.
Clin Infect Dis. 2017 ;64(1):87-91. Epub 2016 Sep 28.Abstract

An epidemiological modelling study to estimate the composition of HIV-positive populations including migrants from endemic settings. 
F Nakagawa, V Delpech, J Albert, A Alioum, D Bezemer, M Cortina-Borja, AE Brown, V Cambiano, C Campbell, D Costagliola, A de Luca, R Kouyos, R Lodwick, JD Lundgren, N Pantazis, C Smith, V Supervie, P Tookey, G Touloumi, Zh Yin, A van Sighem, AN Phillips
AIDS. 2017 ;31(3):417-425. Abstract

4 One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid- susceptible tuberculosis in Eastern Europe, Western Europe and Latin America. D.N. Podlekareva, A. Schultze, A. Panteleev, A.M. Skrahina, J.M. Miro,  A. Rakhmanova, H. Furrer, R.F Miller, A.M. W. Efsen, M.H. Losso, J. Toibaro, A. Vassilenko, E. Girardi, J.D. Lundgren, A. Mocroft, F.A. Post, O. Kirk, on behalf of the TB:HIV study group in EuroCoord.
AIDS. 2017;31(3):375-384. abstract

The clinical utility of PDG PET/CT among solid organ transplant recipients suspected of malignancy or infection. NE Wareham, JD Lundgren, C Da Cuncha-Bang, F Gustafsson, M Iversen, HH Johannesen, A Kjær, A Rasmussen, H Sengeløv, SS Sørensen, BM Fischer.
Eur J Nucl Med Mol Imaging. 2017. Abstract

6 Combination antiretroviral therapy and cancer risk. AH Borges
Current opinion in HIV & AIDS 2017, Vol 11 (6) iv-iv 545-627. Abstract

7 Antiretrovirals, fractures and osteonecrosis in a large international HIV cohort. AH Borges,J Hoy, E Florence, D Sedlacek, HJ Stellbrink, V Uzdaviniene, J Tomazic, P Gargalianos-Kakolyris, P Schmid, C Orkin, C Pedersen, C Leen, C Pradier, F Mulcahy, AL Ridolfo, T Staub, F Maltez, R Weber, L Flamholc, G Kyselyova JD Lungren, A Mocroft; for EuroSIDA.
Clin Infect Dis 2017. Abstract

8 Late presentation of chronic viral hepatitis for medical care: a consensus definition. S Mauss, S Pol, M Buti , E Duffell, C Gore, JV Lazarus ,HL  der Grient, J Lundgren, A Mozalevskis, D Raben, E Schatz, S Wiktor, JK Rockstroh; European consensus working group on late presentation for Viral Hepatitis Care.
BMC Medicine 2017; 15(1):92 abstract

9 Endothelial Damage Signals Refractory Acute Kidney Injury in Critically Ill Patients. TS Itenov, JU Jensen, SR Ostrowski, PI Johansson, KM Thormar, JD Lundgren, MH Bestle; “Procalcitonin And Survival Study” study group.
Shock 2017, 47(6) 696-701. Abstract

10 Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIV-Positive Participants in the START (Strategic Timing of Antiretroviral Treatment) Trial. JV Baker, S Sharma, AC Achhra, JI Bernardino, JR Bogner,  D Duprez, S Emery, B Gazzard, J Gordin, G Grandits, AN Phillips, S Schwarze, EZ Soliman, SA Spector, G Tambussi, J Lundgren; INSIGHT (International Network for Strategic Initiatives in Global HIV Trials) START (Strategic Timing of Antiretroviral Treatment) Study Group.
Journal of the American Heart Association 2017; 6(5). Abstract 

11 Evaluation of HIV testing recommendations in specialty guidelines for the management of HIV indicator conditions. E Lord, AJ Stockdale, R Malek, C Rae, I Sperle, D Raben, A Freedman, D Churchill, J Lundgren, AK Sullivan; British Association of Sexual Health HIV (BASHH)/British HIV Association (BHIVA) guideline review group for the Optimising Testing and Linkage to Care for HIV across Europe (OptTEST) project by HIV in Europeb.
HIV Medicine 2017; 18(4): 300-304. Abstract

12. Bayesian analysis of genetic association across tree-structured routine healthcare data in the UK Biobank. A Cortes, CA Dendrou, A Motyer, L Jostins, D Vukcevic, A Dilthey,P Donnelly, S Leslie, L Fugger, G McVean.
Nat Genet. 2017;49(9):1311-1318. Abstract

13. Risk of infectious diseases among first-degree relatives of transplant recipients who develop CMV infection: is the infectious phenotype inheritable?
C Ekenberg, IP Lodding, NE Wareham, SS Sørensen, H Sengeløv, F Gustafsson, A Rasmussen, M Perch, JD Lundgren, M Helleberg
Eur J Clin Microbiol Infect Dis. 2017. [Epub ahead of print] Abstract

 

14. Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. Baker JV, Sharma S, Grund B, Rupert A, Metcalf JA, Schechter M, Munderi P, Aho I, Emery S, Babiker A, Phillips A, Lundgren JD, Neaton JD, Lane HC; INSIGHT START (Strategic Timing of AntiRetroviral Treatment) Study Group.
Open Forum Infect Dis. 2017;4(4). Abstract

15. Incidental lung cancers and positive computed tomography images in people living with HIV. A Ronit, T Kristensen, DM Klitbo, M Gelpi, A Kalhauge, T Benfield, J Gerstoft, J Lundgren, J Vestbo, KF Kofoed, SD Nielsen  
AIDS 2017; 31(14): 1973-1977. Abstract


16. Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals.  LR Nielsen, A Mocroft, O Kirk, P Reiss, M Ross, C Smith, O Moranne, P Morlat, CA Fux, C Sabin, A Phillips, M Law, JD Lundgren. & D:A:D study group
AIDS 2017 Abstract

17. Forced fluid removal versus usual care in intensive care patients with high-risk acute kidney injury and severe fluid overload (FFAKI): study protocol for a randomised controlled pilot trial.  RE Berthelsen, T Itenov, A Perner, JU Jensen, M Ibsen, AEK Jensen, M Bestle
Trials. 2017 ;18(1):189. Abstract

18. Sepsis – frontiers in resuscitation and infection control. A Perner, AC Gordon, D de Backer, G Dimopoulos, JA Russell, J Lipman, JU Jensen, J Myburgh, M Singer, R Bellomo, T Walsh. 
Intensive Care Medicine 2016;42(12):1958-1969. Abstract 

19. Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. MA Boyd, A Mocroft, L Ryom, AD Monforte, C Sabin , WM El-Sadr,  CIHatleberg, S De Wit, R Weber, E Fontas, A Phillips, F Bonnet, P Reiss, J Lundgren, M Law.
PLoS Med. 2017 ;14(11):. eCollection 2017 Nov. Abstract

20. HIV testing in Europe: Evaluating the impact, added value, relevance and usability of the European Centre for Disease Prevention and Control (ECDC)'s 2010 HIV testing guidance. AK Sullivan, I Sperle, D Raben, AJ Amato-Gauci, JD Lundgren, Y Yazdanpanah, SF Jakobsen, L Tavoschi
Euro Surveill. 2017;22(48). Abstract

21. Are we successfully managing cardiovascular disease in people living with HIV? CI Hatleberg, JD Lundgren, L Ryom.
Curr Opin HIV AIDS. 2017;12(6):594-603Abstract 

22. Global brain atrophy and metabolic dysfunction in LGI1 encephalitis: A prospective multimodal MRI study. M Szots, M Blaabjerg, G Orsi, P Iversen, D Kondziella, CG Madsen, E Garde, PO Magnusson, P Barsi, F Nagy, HR Siebner, Z Illes.
J Neurol Sci. 2017;376:159-165. Abstract

2016

  1. Antiretroviral drugs and risk of chronic ALT elevation in HIV-infected persons without viral hepatitis coinfection. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study H Kovari, CA Sabin, B Ledergerber, L Ryom, P Reiss, M Law, C Pradier, F Dabis, A d’Arminio Monforte, C Smith, S de Wit, O Kirk, JD Lundgren, R Weber , on behalf of the D:A:D Study group. 
    Open Forum Infect Dis. 2016 ;3(1):ofw009. Abstract

  2. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. A Mocroft, JD Lundgren, M Ross, CA Fux  P Reiss, O Moranne, P Morlat, A d'Arminio Monforte, O Kirk, L Ryom, on behalf of The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) Study. 
    Lancet HIV. 2016 ;3(1):e23-32. Abstract

  3. Tuberculosis-related mortality in people living with HIV In Europe and Latin America: an international cohort study. Daria Podlekareva, Anne Marie W. Efsen, Anna Schultze, Frank Post,, Alena M. Skrahina, Alexander Panteleev, Hansjakob Furrer, Robert F. Miller, Marcelo H. Losso, Javier Toibaro, Jose M. Miro, Anna Vassilenko, Enrico Girardi, Mathias Bruyans, Niels Obel, Jens D. Lundgren, Amanda Mocroft, Ole kirk on behalf of the TB:HIV study group in EuroCoord. 
    Lancet HIV. 2016 ;3(3):e120-31. abstract

  4. Identifying key drivers of the impact of an HIV cure intervention in sub-Saharan Africa. A Phillips A, Cambiano, P Revill , F Nakagawa, J Lundgren, L Bansi-Matharu, T Mabugu, M Sculpher, G Garnett, S Staprans, S Becker, J Murungu, SR Lewin, SG Deeks, T Hallett T.*
    J Infect Dis. 2016. 214(1) 73-9. Abstract

  5. Nonnucleoside Reverse-transcriptase Inhibitor- vs Ritonavir-boosted Protease Inhibitor-based Regimens for Initial Treatment of HIV Infection: A Systematic Review and Metaanalysis of Randomized Trials. AH Borges, A Lundh, B Tendal, JA Bartlett, N Clumeck, D Costagliola,ES Daar, P Echeverría, M Gisslén, TB Huedo-Medina, MD Hughes, K Huppler Hullsiek, P Khabo, S Komati, P Kumar, S Lockman, RD MacArthur, F Maggiolo, A Matteelli, JM Miro, S Oka, K Petoumenos, RL Puls, SA Riddler, PE Sax, J Sierra-Madero, C Torti, JD Lundgren.
    Clin Infect Dis. 2016. 63(2) 268-280.  Abstract

  6. IL-6 is a stronger predictor of clinical events than hsCRP or D-dimer during HIV infection. AH Borges,JL O'Connor, AN Phillips, JD Neaton, B Grund, J Neuhaus, MJ Vjecha, A Calmy, KK Koelsch, JD Lundgren; INSIGHT SMART ESPRIT Study Groups.
    J Infect Dis. 2016. 214(3) 408-416 . Abstract 

  7. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study. Amit C Achhra; Amanda Mocroft; Peter Reiss; Caroline Sabin; Lene Ryom; Stephane de Wit; Colette J Smith; Antonella d´arminio Monforte; Andrew Phillips; Rainer Weber;  Jens Lundgren;  Matthew G Law; The D:A:D Study Group.
    HIV Med. 2016 (4):255-68.. abstract

  8. MELD score measured day 10 after orthotopic liver transplantation predicts death and re-transplantation within the first year. AA Rostved, JD Lundgren, J Hillingsø , L Peters, A Mocroft, A Rasmussen.
    Scand J Gastroenterol. 2016, 51 (11), 1360-1366. Abstract

  9. Is Nelfinavir Exposure Associated with Cancer Incidence in HIV-positive individuals? DC Boettinger, CA Sabine, A grulich, L Ryom, F Bonnet, P Reiss, A d'Arminio Monforte, O Kirk, A Phillips, M Bower, G Fätkenheuer, JD Lundgren, M Law. On behalf of the Data collection on Adverse events of Anti-HIV Drugs (D:A:D) study group
    AIDS. 2016 ;30(10):1629-37. Abstract 

  10. Immediate antiretroviral therapy reduces risk of infection-related cancer during early HIV infection. AH Borges, J Neuhaus, AG Babiker, K Henry, MK Jain, A Palfreeman, P Mugyenyi, P Domingo, C Hoffmann, TR Read, S Pujari, M Meulbroek, M Johnson, T Wilkin, R Mitsuyasu. INSIGHT START study Group
    Clin Infect Dis 2016.63(12) 1668-1676. Abstracts

  11. Trends in Incidences and Risk Factors for Hepatocellular Carcinoma and Other Liver Events in HIV and Hepatitis C Virus-coinfected Individuals From 2001 to 2014: A Multicohort Study. Gjærde LI, Shepherd L Jablonowska E, Lazzarin A, Rougemont M, Darling K, Battegay M, Braun D, Martel-Laferriere V, Lundgren JD, Rockstroh JK, Gill J, Rauch A, Mocroft A, Klein MB, Peters L. 
    Clin Infect Dis. 2016 ;63(6):821-9. abstract

  12. Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study. L Ryom, JD  Lundgren, M Ross, O  Kirk, M  Law, P Morlat, C Smit, E Fontas, CA  Fux, CI  Hatleberg, S de Wit, CA Sabin and A Mocroft for the D:A:D Study Group
    J Infect Dis. 2016 ;214(8):1212-20. abstract

  13. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral TherapyAJ. Rodger V Cambiano, T Bruun, P Vernazza, S Collins; J van Lunzen, GM Corbelli; V Estrada, AM Geretti, A Beloukas, D Asboe, P Viciana, F Gutiérrez, B Clotet, C Pradier, J Gerstoft, R Weber, K Westling, G Wandeler, JM. Prins,  A  Rieger, M Stoeckle, T Kümmerle, T Bini,  A Ammassari, R Gilson, I Krznaric,M Ristola, R Zangerle, P Handberg, A Antela, S Allan,  A N. Phillips, J Lundgren, for the PARTNER Study Group 
    JAMA. 2016;316(2):171-181. Abstract

  14. Disparities in HIV clinic care across Europe: findings from the EuroSIDA clinic survey.  JV Lazarus, K Laut, K Safreed-Harmon, L Peters, M Johnson, G Fätkenheuer, I Khromova, L Vandekerckhove, K Maciejewska, R Radoi, AL Ridolfo, A Mocroft, on behalf of EuroSIDA in EuroCoord. 
    BMC Infectious Diseases 2016 16:335. 
    article

  15.  Associations between HIV-RNA-based indicators and virological and clinical outcomes. K Laut, L Shepherd, C Pedersen, JK Rockstroh, H Sambatakou, D Paduta, R Matulionyte, T Smiatacz, F Mulcahy, JD Lundgren, A Mocroft, O Kirk, on behalf of EuroSIDA in EuroCoord.
    AIDS 2016;30(12):1961-72. 
    abstract

  16. Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. JS Jensen, TS Itenov, KM Thormar, L Hein ,TT Mohr, MH Andersen, J Løken, H Tousi, B Lundgren, HC Boesen, ME Johansen, SR Ostrowski, PI Johansson, J Grarup, J Vestbo, JD Lundgren; Procalcitonin And Survival Study (PASS) Group.
     Ann Intensive Care. 2016 ;6(1):114. Abstract

  17. Improvements over time in short-term mortality following myocardial infarctions in HIV-positive individuals. CI Hatleberg, L Ryom, W El-Sadr, C Smith, R Weber, P Reiss, E Fontas, F Dabis, M Law, A d'Arminio Monforte, S de Wit, A Mocroft, A Phillips, JD Lundgren, C Sabin. On behalf of the D:A:D Study Group.
    AIDS 2016, 30:1583-1596. Abstract 

  18. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: a prospective cohort study JM Llibre, A Cozzi-Lepri, C Pedersen, M Ristola, M Losso, A Mocroft, V Mitsura, K Falconer, F Maltez, M Beniowski, V Vullo, G Hassoun, E Kuzovatova, J Szlavik, A Kuznetsova, H-J Stellbrink, C Duvivier, S Edwards, K Laut, R Paredes for the EuroSIDA Study Group. 
    Medicine 2016, Volume 95(40),  abstract

  19. The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. S Lodi, S Sharma, JD Lundgren, AN Phillips, SR Cole, R Logan, BK Agan, A Babiker, H Klinker, H Chu, M Law, JD Neaton, MA Hernán, INSIGHT Strategic Timing of Antiretroviral Treatment (START) study group.
    AIDS 2016, 30(17) 2659-2663. Abstract 

  20. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. KM Kunisaki, DE Niewoehner, G Collins, B Aagaard, NB Atako, E Bakowska, A Clarke, GM Corbelli, E Ekong, S Emery, EB Finley, E Florence, RM Infante, CM Kityo, JS Madero, DE Nixon, E Tedaldi, J Vestbo, R Wood, JE Connett; INSIGHT START Pulmonary Substudy Group.
    Lancet Respir Med. 2016, 4(12) 980-989. Abstract

 

2015

  1. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D StudyA Mocroft, JD Lundgren, M Ross, M Law, P Reiss, O Kirk, C Smith, D Wentworth, J Neuhaus, C A. Fux, O Moranne, P Morlat, MA Johnson, L Ryom, D:A:D study group, the Royal Free Hospital Clinic Cohort, and the INSIGHT, SMART, and ESPRIT study groups 
    PLoS Med 2015, 12 (3)


  2. Clinical Application of Variation in Replication Kinetics During Episodes of Post-transplant Cytomegalovirus Infections, IP Lodding, H Sengeløv, C da Cunha-Bang, M Iversen, A Rasmussen, F Gustafsson, JG Downing, J Grarup, N Kirkeby, CM Frederiksen, A Mocroft, SS Sørensen, JD Lundgren,
    On behalf of the MATCH Programme Study Group
    EBioMedicine; 2015 Vol 2, Issue 7 p.669-705


  3. Factors Associated with Plasma IL-6 Levels During HIV Infection,  ÁH Borges, JL O'Connor, AN Phillips, FF Rönsholt, S Pett, MJ Vjecha, MA French, JD Lundgren, INSIGHT, SMART and ESPRIT Study Groups and the SILCAAT Scientific Committee
    J Infect Dis. 2015. 212, 585- 595


  4. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection, The INSIGHT START Study Group, JD Lundgren, AG Babiker , F Gordin, S Emery, B Grund, S Sharma, A Avihingsanon, DA Cooper, G Fätkenheuer, JM Llibre, J Molina, P Munderi, M Schechter, R Wood, KL Klingman, S Collins, HC Lane, AN Phillips, JD Neaton, The INSIGHT START Study Group 
    New England J Med 2015, 373: 795-807 

  5. Late presentation for HIV care across Europe: Update from the collaboration of observational HIV epidemiological research Europe (COHERE) Study 2010 to 2013, The late presenters working group in COHERE in EuroCoord,  A Mocroft et. al.
    Eurosurveillance 2015 Vol 20, Issue 47

  6. Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa, Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, Bonner K, Rousseau C, Garnett G, Cambiano V, Nakagawa F, Ford D, Bansi-Matharu L, Miners A, Lundgren JD, Eaton JW, Parkes-Ratanshi R, Katz Z, Maman D, Ford N, Vitoria M, Doherty M, Dowdy D, Nichols B, Murtagh M, Wareham M, Palamountain KM, Chakanyuka Musanhu C, Stevens W, Katzenstein D, Ciaranello A, Barnabas R, Braithwaite RS, Bendavid E, Nathoo KJ, van de Vijver D, Wilson DP, Holmes C, Bershteyn A, Walker S, Raizes E, Jani I, Nelson LJ, Peeling R, Terris-Prestholt F, Murungu J, Mutasa-Apollo T, Hallett TB, Revill P. 
    Nature. 2015 ;528(7580):S68-76.